[1]袁 利,程明刚,刘香萍,等.深圳地区健康育龄妇女血清中AMH水平现况及其在PCOS和POF诊疗中的价值[J].现代检验医学杂志,2017,32(05):141-144.[doi:10.3969/j.issn.1671-7414.2017.05.017]
　YUAN Li,CHENG Ming-gang,LIU Xiang-ping,et al.Status of AMH in Serum of Healthy Women in Shenzhen Area and Its Value in PCOS and POF Treatment[J].Journal of Modern Laboratory Medicine,2017,32(05):141-144.[doi:10.3969/j.issn.1671-7414.2017.05.017]
点击复制

深圳地区健康育龄妇女血清中AMH水平现况及其在PCOS和POF诊疗中的价值()
分享到：

《现代检验医学杂志》[ISSN:/CN:]

卷:
第32卷
期数:
2017年05期
页码:
141-144
栏目:
检验与临床
出版日期:
2017-11-02

文章信息/Info

Title:
Status of AMH in Serum of Healthy Women in Shenzhen Area and Its Value in PCOS and POF Treatment
文章编号:
1671-7414(2017)05-141-04
作者:
袁 利; 程明刚; 刘香萍; 徐羽中; 李小永
深圳市宝安区人民医院检验科,广东深圳 518100
Author(s):
YUAN Li; CHENG Ming-gang; LIU Xiang-ping; XU Yu-zhong; LI Xiao-yong
Department of Clinical Laboratory, Shenzhen Baoan District People's Hospital,Guangdong Shenzhen 518100,China
关键词:
育龄妇女;  抗苗勒氏管激素;  现况;  多囊卵巢综合征;  卵巢早衰;  价值
分类号:
R711.75; R392.11
DOI:
10.3969/j.issn.1671-7414.2017.05.017
文献标志码:
A
摘要:
目的 了解深圳地区健康育龄妇女血清中抗苗勒氏管激素(anti-Mullerian hormone,AMH)水平现况,并探讨其在多囊卵巢综合征(PCOS)和卵巢早衰(POF)诊疗中的价值。方法 收集2016年1月～2017年3月来深圳市宝安区人民医院体检的健康育龄妇女860例为对照组,并选择同期就诊的PCOS患者59例和POF患者61例,采用DXI800化学发光分析仪分别检测对照组、PCOS和POF组患者治疗前及治疗3个月后血清中AMH水平,并对检测结果进行统计分析。结果 健康育龄妇女血清中AMH水平为4.91±1.56 ng/ml,其中18～25岁组为5.38±1.27 ng/ml,31～35岁组和36～42岁组分别为4.53±1.40 ng/ml和3.95±1.16 ng/ml,明显低于18～25岁组,差异有统计学意义(t=3.082,5.066,均P<0.05),而26～30岁组为5.09±1.45 ng/ml,与18～25岁组之间差异无统计学意义(t=0.892,P>0.05)。治疗前,PCOS患者血清中AMH水平为10.13±3.85 ng/ml,明显高于对照组,差异有统计学意义(t=13.924,P<0.01),而POF组和围POF组患者血清中AMH水平分别为1.04±0.37 ng/ml和2.39±0.87 ng/ml,明显低于对照组,差异有统计学意义(t=10.913,8.042,均P<0.05),且POF组低于围POF组,差异有统计学意义(t=2.875,P<0.05)。治疗后,PCOS患者血清中AMH水平为5.22±1.58 ng/ml,明显低于治疗前,差异有统计学意义(t=11.106,P<0.05),而与对照组之间差异无统计学意义(t=1.036,P>0.05),POF组和围POF组患者血清中AMH分别为4.49±1.32ng/ml和4.54±1.47 ng/ml,明显高于治疗前,差异有统计学意义(t=9.608,7.253,均P<0.05),而与对照组之间差异均无统计学意义(t=1.209,0.918,均P>0.05)。结论 治疗前,PCOS患者血清中AMH水平明显升高,POF和围POF患者血清中明显降低,而治疗后PCOS,POF和围POF患者血清中AMH水平均恢复正常。因此,AMH在PCOS和POF疾病诊疗中具有一定的应用价值,值得推广应用。
Abstract:
Abstract:Objective To investigate the current status ofanti-mullerian hormone(AMH)in healthy women in the healthy childbearing age in Shenzhen area,and to explore its application value in polycystic ovary syndrome(PCOS)and prature ovarian syndrome(POF)treatment.Methods Collected 860 cases of medical health women of childbearing age in Shenzhen Baoan District People's Hospital from January 2016 to March 2017 as control group,and at the same time selected 59 cases of patients with PCOS and 61 cases of patients with POF as observation group.Adopted DXI800 chemiluminescence analyzer to test serum AMH level of control group,patients with PCOS and POF group respectively before and 3 months after treatment,and the testing results were analyzed.Results The serum AMH level of Healthy women of childbearing age was 4.91±1.56 ng/ml,18～25 years old group was 5.38±1.27 ng/ml,31～35 and 36～42 years old group were 4.53±1.40 ng/ml and 3.95±1.16 ng/ml,being all lower than that in group 18～25 years old(t=3.082,5.066,all P<0.05).While 26～30 years old group was 5.09±1.45 ng/ml,and compared with 18～25,there was no statistically significant difference(t=0.892,P>0.05).Before the treatment,the serum AMH level of PCOS was 10.13±3.85 ng/ml,significantly higher than the control group,the difference was statistically significant(t=13.924,P<0.01),while the serum AMH level of POF group and wait POF patients were 1.04±0.37 ng/ml and 2.39±0.87 ng/ml,significantly lower than the control group(t=10.913,8.042,all P<0.05),and POF lower than wait POF group(t=2.875,P<0.05).After treatment,the serum AMH level of PCOS was 5.22±1.58 ng/ml,significantly lower than before treatment(t=11.106,P<0.05),and there was no statistically significant difference between control group(t=1.036,P>0.05),the serum AMH level of POF and wait POF were 4.49±1.32 ng/ml and 4.54±1.47 ng/ml,significantly higher than the before treatment(t=9.608,7.253,all P<0.05),and compared with the control group there were no statistically significant differences(t=1.209,0.918,all P>0.05).Conclusion Before the treatment,the serum AMH levels of PCOS were increased significantly,and the serum AMH levels of POF and wait POF patients were significantly reduced,while the serum AMH levels of PCOS,POF and wait POF patients were all restored to normal levels after treatment.Therefore,AMH has certain application value in the diagnosis and treatment evaluation of women PCOS and POF disease.

参考文献/References:

[1] Hossain MM,Cao M,Wang Q,et al.Altered expression of miRNAs ina dihydrotestosterone-induced rat PCOS model[J].J Ovarian Res,2013,6(1):36.
[2] 蔡旱育,戴伟良,徐杰伟.抗苗勒管激素检测在多囊卵巢综合征治疗前后的临床意义[J].实用医技杂志,2017,24(1):57-58. Cai HY,Dai WL,Xu JW.Clinical significance of anti-Mullerian hormone test before and after treatment of polycystic ovary syndrome[J].Journal of Practical Medical Techniques,2017,24(1):57-58.
[3] 刘建华.血清抗苗勒管激素联合性激素检测在预测卵巢早衰中的临床意义[J].哈尔滨医药,2013,33(3):181-182. Liu JH.Clinical significance of serum anti-Mullerian hormone and sex hormones test in premature ovarian failure[J].Harbin Medical Journal,2013,33(3):181-182.
[4] Hansen KR,Hodnett GM,Knowlton N,et al.Correlation of ovarian reservetests with histologically determined primordial follicle number[J].Fertil Steril,2011,95(1):170-175.
[5] 丛 青,李 斌.卵巢早衰的病因与诊治进展[J].老年医学与保健,2015,21(6):339-342. Cong Q,Li B.Etiology,diagnosis and treatment of premature ovarianfailure[J].Geriatrics & Health Care,2015,21(6):339-342.
[6] Karkanaki A,Vosnakis C,Panidis D.The clinical significance of anti-Mullerian hormone evaluation in gynecological endocrinology[J].Hormones(Athens,Greece),2011,10(2):95-103.
[7] Jeppesen JV,Anderson RA,Kelsey TW,et al.Which follicles make the mostanti-Mullerian hormone in humans? Evidence for an abrupt decline in AMH production at the time of follicle selection[J].Mol Hum Reprod,2013,19(8):519-527.
[8] Dewailly D,Andersen CY,Balen A,et al.The physiology and clinical utility of anti-Mullerian hormone in women[J].Hum Reprod Update,2014,20(3):370-385.
[9] Kelsey TW,Wright P,Nelson SM,et al.A validated model of serum anti-mullerian hormone from conception to menopause[J].PLoS One,2011,6(7):e22024.
[10] 谢文光,林晓桃,陈文锋.抗苗勒管激素在多囊卵巢综合征中的诊断意义[J].国际检验医学杂志,2016,37(21):3081-3083. Xie WG,Lin XT,Chen WF.The diagnostic value of anti Mullerian hormone inpolycystic ovary syndrome[J].International Journal of Laboratory Medicine,2016,37(21); 3081-3083.
[11] Leonhardt H,Hellstrom M,Gull B,et al.Ovarian morphology assessed bymagnetic resonance imaging in women with and without polycystic ovary syndrome and associations with antimullerian hormone,free testosterone,and glucose disposal rate[J].Fertil Steril,2014,101(6):1747-1756.
[12] Kelsey TW,Anderson RA,Wright P,et al.Data-driven assessment of thehuman ovarian reserve[J].Mol Hum Reprod,2012,18(2):79-87.
[13] Nelson SM,Anderson RA,Broekmans FJ,et al.Anti-Mullerian hormone:clairvoyance or crystal clear[J].Hum Reprod,2012,27(3):631-636.
[14] Van Disseldorp J,Lambalk CB,Kwee J,et al.Comparison of inter-and intra-cycle variability of anti-Mullerian hormone and antral follicle counts[J].Hum Reprod,2010,25(1):221-227.
[15] 李 璐,李 鹏.血清抗苗勒管激素在多囊卵巢综合征诊治中的临床应用价值[J].中国妇产科临床杂志,2016,17(6):551-553. Li L,Li P.Clinical value of serum anti Mullerian hormone in the diagnosis and treatment of polycystic ovary syndrome[J].Chinese Journal of Clinical Obstetrics and Gynecology,2016,17(6):551-553.
[16] 游红霞,张静宇,张玉蕊.卵巢早衰患者卵巢功能评估及护理[J].护理实践与研究,2016,13(17):92-93. You HX,Zhang JY,Zhang YR.The ovarian function of patients with ovarianpremature aging assessment and nursing[J].Nursing Practice and Research,2016,13(17):92-93.
[17] 杨小岗,王 芳,武佳敏,等.血清抗苗勒管激素诊断卵巢早衰的临床意义[J].检验医学与临床,2010,7(1):51-52. Yang XG,Wang F,Wu JM,et al.Clinical significa-nce of serum anti-Mullerian hormone to diagnosis of ovarian premature aging[J].Laboratory Medicineand Clinic,2010,7(1):51-52.

相似文献/References:

[1]董 莉,张保平,冯新平,等.血清雄性激素、AMH检测 在女性不孕诊断中的应用价值[J].现代检验医学杂志,2016,31(03):77.[doi:10.3969/j.issn.1671-7414.2016.03.021]
　DONG Li,ZHANG Bao-ping,FENG Xin-ping,et al.Value of Testing Serum Testosterone and AMH in the Diagnosis of Female Infertility[J].Journal of Modern Laboratory Medicine,2016,31(05):77.[doi:10.3969/j.issn.1671-7414.2016.03.021]
[2]归巧娣,苍金荣,宫艳艳,等.西安地区育龄妇女MTHFRC677T基因型分布研究[J].现代检验医学杂志,2015,30(06):39.[doi:10.3969/j.issn.1671-7414.2015.06.011]
　GUI Qiao-di,CANG Jin-rong,GONG Yan-yan,et al.Geographical Distribution of MTHFRC677T Gene among the Gestational Age Women in Xi’an[J].Journal of Modern Laboratory Medicine,2015,30(05):39.[doi:10.3969/j.issn.1671-7414.2015.06.011]
[3]李　凯,李相新,文海军,等.2016~2018 年广东省佛山地区育龄妇女细小病毒B19 的感染情况分析[J].现代检验医学杂志,2020,35(03):120.[doi:10.3969 ／ j.issn.1671-7414.2020.03.032]
　LI Kai,LI Xiang-xin,WEN Hai-jun,et al.Analysis of Parvovirus B19 Infection in Women of Childbearing Age in Foshan of Guangdong from 2016 to 2018[J].Journal of Modern Laboratory Medicine,2020,35(05):120.[doi:10.3969 ／ j.issn.1671-7414.2020.03.032]
[4]左江成a,邓琛琛a,杨　洁a,等.湖北宜昌市育龄妇女和母婴巨细胞病毒感染现状调查及感染风险评估[J].现代检验医学杂志,2020,35(06):91.[doi:doi:10.3969/j.issn.1671-7414.2020.06.022]
　ZUO Jiang-cheng a,DENG Chen-chen a,YANG Jie a,et al.Investigation on Status and Risk Assessment of Cytomegalovirus Infection inWomen of Childbearing Age and Maternals and Infants in Yichang, Hubei[J].Journal of Modern Laboratory Medicine,2020,35(05):91.[doi:doi:10.3969/j.issn.1671-7414.2020.06.022]

备注/Memo

备注/Memo:
作者简介:袁 利(1980-),女,本科,主管技师,主要从事生化免疫和微生物工作,E-mail:yuanli1980_1@163.com。
更新日期/Last Update: 1900-01-01